Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China
Launched by PEKING UNIVERSITY THIRD HOSPITAL · May 9, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the ChiTwiMC study, is looking into how twin pregnancies affect both mothers and their babies in China. Specifically, it aims to understand different complications that can occur during twin pregnancies, such as pre-term birth and other health issues related to having twins. The study is being led by a team at Peking University Third Hospital, and it is currently recruiting female participants who are expecting twins.
To be eligible for this study, women must be between the ages of 18 and 45, have a twin pregnancy that is less than 14 weeks along, and plan to receive prenatal care at the study hospital. Participants will need to sign a consent form to join. This study is important because it will help healthcare providers better understand the risks and needs of women with twin pregnancies, ultimately leading to improved care and outcomes for mothers and their children.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Twin pregnancies
- • Female aged between 18-45 years
- • Gestational age is less than 14 weeks
- • Planning to receive prenatal healthcare and delivery service at the study hospital
- • Signing informed concent and willing to participate
- Exclusion Criteria:
- • Women with mental disorders or serious maternal illness that is not eligible to participate
- • Inability to provide informed consent
- • Pregnant women not registered in our hospital
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jinan, Shandong, China
Jinan, Shandong, China
Guangzhou, Guangdong, China
Shanghai, Shanghai, China
Shenyang, Liaoning, China
Hefei, Anhui, China
Peking, Beijing, China
Peking, Beijing, China
Chongqing, Chongqing, China
Shanghai, Shanghai, China
Tianjin, Tianjin, China
Patients applied
Trial Officials
Yuan Wei, PhD, MD
Study Chair
Obstetrics and Gynecology Department of Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported